|Day Low/High||11.25 / 11.66|
|52 Wk Low/High||4.83 / 23.59|
Conference Call Scheduled for Thursday, March 16, 2017 at 8:30 a.m. ET
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Investors eyeing a purchase of Karyopharm Therapeutics Inc stock, but tentative about paying the going market price of $10.05/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the August put at the $7.50 strike, which has a bid at the time of this writing of 85 cents.
The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 289,025 share increase in total short interest for Karyopharm Therapeutics Inc , to 1,756,850, an increase of 19.69% since 12/15/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
- Webcast Event Scheduled for Monday, December 5, 2016 at 8:15 PM PT -
Celebration Commemorating the Company's 8th Anniversary
Conference Call Scheduled for Monday, November 7, 2016 at 5:00 p.m. ET
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors considering a purchase of Karyopharm Therapeutics Inc shares, but tentative about paying the going market price of $8.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February 2017 put at the $7.50 strike, which has a bid at the time of this writing of 80 cents.
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.